BTK and pancreatic ductal adenocarcinoma: Association of BTK was evident in a study using the BTK inhibitor ibrutinib on pancreatic ductal adenocarcinoma (PDAC)-bearing mice, which resulted in the termination of PDAC growth by deviating macrophages to target T(H)1 phenotype involved in CD8(+) T-cell cytotoxicity paralleled with a boost in chemotherapy responsiveness [46].